Editor-We agree with Hawton and Williams that training courses for careers in the media offer the potential for improved portrayal of suicide in the media.
Media influence behaviour
Editor-Hawton and Williams's study provides evidence that supports an argument for (increased) awareness among media producers and editors about their potential influence on the public over health matters. 1 Howe et al in response note the effect on the NHS cervical screening programme of a television character's death (Alma in Coronation Street) from cervical cancer (letter above). We examined the impact of the same television story and related tabloid newspaper reporting on inquiries made to CancerBACUP's helpline (the United Kingdom's leading cancer information charity, www.cancerbacup.org.uk).
The change in the volume and content of calls during the three months between the story "breaking" in the Sun newspaper and Alma's eventual death, compared with calls received in the three months before the story, supports Hawton and Williams's work. 1 Peaks in inquiries about cervical cancer occurred on three occasions, directly coinciding with developments in the storyline (figure). The story triggered up to 300 additional weekly enquiries to Cancer-BACUP. Evidence corroborated Hawton and Williams's suggestion of a similarity between media stimulus and the viewer in terms of age, sex, and nationality. 1 Data showed a slight increase in the proportion of calls from women in their 50s and 60s; the actor who played Alma was 63 years old.
In the three months before the storyline just 6.7% of people telephoning Cancer-BACUP about cervical cancer said that they had first heard about the charity via a newspaper or the television. This percentage rose to 41.8% while the storyline was in progress. Furthermore, the proportion of inquiries from homemakers and retired people more than doubled compared with calls during the previous three months.
Our research has questions left unanswered. What, for example, became of the people whom the Coronation Street story worried but who did not contact Cancer-BACUP? Did they contact other information services or their general practitioner, or did they remain concerned, probably unnecessarily, about the risk of cervical cancer? What is clear is the potential for media to impinge on the viewing public in a marked, and in this case measurable, way.
The trend for giving information at the end of potentially delicate television programmes seems not only responsible but necessary. In our study making such information available led to the use of a cancer helpline by a broad and, in part, previously untapped group. 
Rachel Hardyman research officer

Media's role is double edged
Editor-The alarming escalation of charcoal burning suicide in Hong Kong supports Hawton and Williams's call for guidelines on the reporting of suicide. 1 We previously reported on the emergence of this new method of suicide in Hong Kong. 2 In November 1998 a 35 year old woman committed suicide by burning charcoal in a barbeque grill in her sealed and cramped apartment. Compared with jumping, which accounts for most local suicide deaths, suicide by burning charcoal was romanticised as an easy and comfortable way of dying. The incident was pictorially reported in the media. Two months after its appearance charcoal burning became the third commonest method of suicide in Hong Kong, where carbon monoxide poisoning was previously uncommon. 2 In 2001 it replaced hanging as the second commonest method of suicide, accounting for 25% of all deaths from suicide.
People committing suicide by charcoal burning were often middle aged and were portrayed as debt ridden because Hong Kong was experiencing its first recession after two decades of economic boom. Charcoal burning was represented as a legitimate way out of the person's financial predicaments. Our coroner's court findings were highly consistent with these media representations. 2 The influence of the media on suicide is contentious and has not been taken seriously in public health. 3 4 In the case of suicide by charcoal burning in Hong Kong, concerns have been raised by researchers and healthcare workers about the potentially contagious impact of media reporting. However, news editors have expressed reservations and remain unconvinced about the guidelines published by the World Health Organization on suicide reporting.
The first suicide intervention and prevention centre in China, funded by the Chinese government, was opened in December in Beijing. Media publicity was rightly adopted as one of the key strategies for raising public awareness. 5 None the less, given that the handy use of pesticides claimed most of the suicide deaths in rural China, the possible effect of such publicity deserves monitoring too.
Death risk other than from suicide is raised in self harm
Editor-Jenkins et al report on continuing suicide risk after deliberate self harm. 1 They use their findings to argue that clinicians should pay close attention to continuing risk of suicide in people with a history of deliberate self harm. Their findings, in a cohort from the late 1970s, are similar to findings from a 1981 Scottish discharge cohort. 2 Using the Scottish linked dataset we followed up a cohort of 8304 people discharged over a 13 year period from Scottish general hospitals after deliberate self harm. We found that the greatest number of deaths from suicide or undetermined cause were in the five years after discharge. In the third five year period, however, the ratio of observed self harm to expected self harm was 5.33 (95% confidence interval 3.26 to 8.23) for men and 9.46 (5.61 to 14.95) for women. Homicides and accidental deaths were also raised.
We endorse the advice by Jenkins et al that clinicians should pay attention to suicide risk but think that their method may have concealed another important clinical implication. They note that people who had consumed alcohol at the time of the initial episode were less likely to be traced. They also censored the 13 deaths in their cohort that were not attributed to definite or probable suicide.
In the Scottish cohort, we examined deaths by suicide and undetermined cause, and deaths by other causes. Altogether 214 people died by suicide or undetermined cause during the follow up period, 196 more deaths than expected. Nine other categories of illness, however, accounted for 780 deaths, 344 more than would have been expected at general population rates. Natural causes, therefore, were responsible for more excess deaths than were suicides.
We identified a higher risk of digestive system disease, respiratory and circulatory disease, and cancers. The pattern indicates to us that alcohol, as well as unhealthy lifestyles and possibly impaired access to medical care, may be important in this group of people. Clinicians should pay attention to alcohol use and physical health as well as suicide risk in people with a history of deliberate self harm. 
Cameron Stark honorary senior lecturer
Low dosage tricyclic antidepressants in depression
Giving low dose tricyclics is not justified by evidence
Editor-The meta-analysis by Furakawa et al must be considered downright naughty. 1 While masquerading as a contribution to an academic debate about appropriate antidepressant treatment it actually does little more than endorse the widely held prejudice in favour of using low dose tricyclics in depression. Published in a widely read UK general medical journal, it will inevitably encourage a practice that is not encouraged by either the Royal College of Psychiatrists or the American Psychiatric Association. The subject of optimal dosage of tricyclics remains controversial, but the value of treatment with tricyclic antidepressants at standard dosage compared with placebo is abundantly clear. As Furakawa et al concede but perhaps do not emphasise sufficiently, the evidence for low dose tricyclic antidepressants is of generally poor quality. Many of the trials used in their analysis took place before standardised diagnostic or outcome criteria were commonplace.
What is less clear is the motivation for their undertaking. Fluoxetine is now available in generic preparations for about £7 per month, significantly reducing the financial advantage of older antidepressants. Some evidence supports the use of tricyclics in severe depression, but presumably the authors would not recommend low dose tricyclics in such patients. The chronic severe nature of depression would make it unethical to recommend a treatment without a secure evidence base. Being charitable, one can only hope that the therapeutic advice was added to add colour to an otherwise unexceptional meta-analysis. 
Hugh M Jones specialist registrar
Evidence to change current guidelines is insufficient
Editor-The study by Furukawa et al consists of two separate analyses looking at quite different things so it is difficult to draw any firm conclusions. 1 The first meta-analysis of 35 studies indicates that tricyclic antidepressants given at low dosage may improve certain symptoms, some of which may be secondary to depression. This has already been established, and, as respondents on bmj.com have pointed out, low dose tricyclics are commonly used to treat chronic pain, insomnia, and anxiety, whether these symptoms occur secondary to a depressive illness, as part of self limiting adjustment and anxiety disorders, or independently. 2 The question that remains unanswered is whether low dose tricyclics can adequately treat an episode of clinical depression. Furukawa et al are careful to say only that their meta-analysis shows that low dose tricyclics are more effective than placebo.
The second meta-analysis, which examines whether low dose tricyclics are as effective as recommended doses in the treatment of depressive illness, is only six studies with 551 patients. The authors acknowledge some of the weaknesses in their analysis (heterogeneity of the studies, the quality of some studies, the adequacy of blinding, and the lack of operational criteria and interview schedules to diagnose depression). Respondents on bmj.com have also pointed out that the cut-off point for a therapeutic dose is incorrect as most authorities recognise that 125 mg, not 100 mg, is the minimum recommended dose. 2 The only useful result to come out of this small analysis is therefore that patients do not tolerate higher doses as well as low doses of tricyclics. Again, this is an already established finding and adds nothing new to the debate.
My concern is that this meta-analysis will be misinterpreted and will deter clinicians from prescribing recommended doses of tricyclics and thereby fail to treat depressive illness adequately. A report in Hospital Doctor, that the use of low dose tricyclics in depression is "vindicated," confirms my fear. Competing interests: IMA has received funding from Eli Lilly for a study and a few small honorariums for talking to professionals on the management of depression, as well as having attended conferences and symposia, some of which were sponsored by various pharmaceutical companies. 
Non-superiority does not equal equivalence
Editor-In their comprehensive metaanalysis of tricyclic antidepressants, Furukawa et al addressed the important question of dose-response. 1 This meta-analysis provides a further opportunity to learn about the concept of equivalence in meta-analysis.
A key question that practitioners will ask of this meta-analysis is whether low doses of tricyclics are equivalent to standard doses.
However, in the absence of a clearly devoted research question, it remains unclear whether this review was intended as a superiority or equivalence trial. This should be clarified for practitioners as these concepts are not immediately intuitive.
The message that low dose tricyclics may or may not be as effective as standard dosage tricyclics was correctly asserted in the original paper. However, Furukawa misleadingly says on bmj.com that an earlier Canadian meta-analysis had shown that selective serotonin reuptake inhibitors in standard dosage are as effective as tertiary amine antidepressants in low and standard dosages. 2 3 In contrast to the earlier statement by Furukawa et al, indicating non-superiority between standard and low dose tricyclics in their meta-analysis, this statement claims that the Canadian meta-analysis showed that selective serotonin reuptake inhibitors are as effective as tricyclics.
These concepts, non-superiority and equivalence, are keenly different. 4 Equivalence cannot be safely defined simply as overlapping confidence intervals, as is inferred above from the Canadian study, which did not explicitly set out to prove equivalence. Rather, if proving equivalence is the intention, then objective criteria should be defined a priori, as for example, 95% confidence intervals within the bounds of 0.90 to 1.10 for an aggregate relative effect size of 1.00.
Theory aside, how shall practitioners interpret this meta-analysis? As Furukawa et al have said, standard dosage is not significantly better than low dosage. But this does not infer that low or standard dosage is better or worse than the other. Equally important, neither does it mean they are the same. The bottom line is that we remain uncertain whether standard and low doses are the same or different. The outer limits of the 95% confidence intervals define just how different they might be, and the possibility of clinically important differences cannot be ruled out. Much larger studies are needed to bring these bounds within the threshold of an acceptable definition of equivalence. 
Authors' reply
Editor-Jones questions our motivation for undertaking this meta-analysis. It was simple. We surveyed psychiatric practices in Japan and found that benzodiazepines were often given with antidepressants and that tricyclic antidepressants were often given in "inadequate dosage." We condemned these practices. 1 Then, however, we wondered if there was enough evidence to say this. We therefore undertook two meta-analyses, one of combined treatment with antidepressants and benzodiazepines and another of tricyclics at low dosage. The first one found that our reproof may be wrong: the combined treatment brought about more response than antidepressant alone up to four weeks. 2 The second meta-analysis again showed that our reprimand (along with similar claims by many others) was ill founded.
However, some of Ali's concerns are understandable. For lack of space, we could not report all sensitivity analyses examining possible confounders.
Firstly, we limited our analyses to those using operationalised criteria; the results were essentially identical.
Secondly, we conducted several subgroup analyses (planned a priori) on older people, patients in primary care, and psychiatric patients. The results were all compatible with the overall results. The details of these sensitivity and subgroup analyses will soon be available in the Cochrane Library.
We agree with Martin's argument on non-superiority and equivalence. The plausible ranges of absolute benefit increase of response for standard dosage over low dosage, on the basis of the 95% confidence intervals of relative risks and the average control event rates, are 6% (95% confidence interval − 4% to 14%) at four weeks and − 4% ( − 24% to 9%) at six to eight weeks; that of absolute risk increase of dropout owing to side effects is 9% (4% to 12%).
Thus clinically important increases in benefit on standard dosage over low dosage cannot be ruled out. At the same time, the increases point to a roughly equal number of patients who drop out because of side effects. We remain uncertain whether standard and low doses are the same or different, but it seems clear to us that we should not try to increase the dosage above 100 mg or 125 mg up front for patients with depression.
So, we must not turn the argument upside down, as does Jones. If a metaanalysis does not support a certain practice recommended by a guideline, is it this part of the guideline that may be wrong or is it the meta-analysis?
Regulatory bodies can root out corruption
Editor-Wilmshurst described institutional corruption in medicine. 1 In Queensland the Nursing Act enables the Queensland Nursing Council to appoint inspectors. Acts regulating other health professions, including medicine, also have similar powers. Inspectors can require the production of documents, etc, and can enter and search for evidence of breaches of the act. The inspectors can also apply to a magistrate for a warrant, and it is an offence to obstruct an inspector.
These are fairly draconian powers, but they were born out of an era of widespread corruption of the state government and the enormous difficulty a subsequent inquiry had in rooting out offenders.
Obviously, the council does not use these powers as a first recourse. It is also my perception that universities here have very good relations with regulatory bodies and would probably cooperate fully with a legitimate investigation. Usually the appropriate councils will investigate complaints confidentially and bring material into the public arena only if a matter goes to a hearing. Thus there is generally no damage to an institution's reputation until that stage, by which time they may have deserved the damage.
I suggest that, if Wilmshurst's complaints are indicative of a common practice, amendments be made to the legislation regulating medicine along the lines of the Queensland act. The powers do not have to be used, but they may be useful in reminding recalcitrants and those who would obstruct investigations that failure to cooperate is not acceptable.
With the General Medical Council attempting to improve the reputation of the profession after the scandals of recent years, it does not need the behaviours described by Wilmshurst. 
Mortality from methicillin resistant Staphylococcus aureus
Welsh surveillance data show plateau
Editor-Crowcroft and Catchpole conclude from a study of death certificates that infections due to methicillin resistant Staphylococcus aureus are an increasing cause of mortality in England and Wales. 1 That this was likely to have been the case in Wales over the period of their study, 1993-8, is supported by surveillance data, which show a large rise in bacteraemias caused by S aureus between 1991 and 1997 ( figure) .
This can largely be attributed to increasing occurrence of methicillin resistant S aureus as a cause of these infections from 1993, although a smaller rise in methicillin sensitive S aureus bacteraemias was also recorded. The degree to which this increase in staphylococcal bacteraemias has affected outcomes in relation to the underlying clinical conditions is, however, unknown, and for the reasons pointed out by Liggett and Swift in their electronic response cannot be accurately inferred from data derived from death certificates. 2 The Welsh surveillance data do not support the statement that the number of infections caused by methicillin resistant S aureus is continuing to increase every year in England and Wales and the supposition that mortality is also continuing to rise. The number of bacteraemias in Wales has changed little since 1997, and laboratory reports relating to overall numbers of isolates from infected and colonised patients reached a plateau in 2000 after a comparatively small rise between 1998 and 2000 (5650 to 6031 reports).
Presumably the steady state that has been achieved reflects the interaction of the innate transmissibility and virulence of the S aureus clones circulating; the ability to prevent transmission and infection; and the selective pressure exerted by usage of antibiotics. To shift this steady state and reduce the overall burden of disease caused by S aureus new initiatives that prevent transmission and infection and reduce the selective pressure from using antibiotics will need to be introduced on a wide scale. 
Is death by disease or treatment?
Editor-The past practice of isolating patients with severe neutropenia arising from cancer chemotherapy was abandoned when studies showed that isolation did not prevent the spread of hospital infections to these immunologically suppressed patients. Isolation protocols increased mortality even in this predominantly younger population. It was hypothesised that the bother of donning gloves and gowns deterred hospital staff from entering the patient's isolation room, thereby depriving the patient of effective communication with staff, as well as limiting professional observation and physical examination. This begs the question to what extent death is caused by methicillin resistant Staphylococcus aureus itself as opposed to the isolation treatment.
Isolation protocols not only include encumbrances on professional staff from physically accessing a patient but, more importantly, severely inhibit patients from leaving their hospital bedroom, limiting both their physical activity and appetite. Out of sheer boredom the patient spends most of the day horizontal in bed. The ravages of excessive bedrest were noted by Asher-not least, hypostatic pneumonia, hypercalcaemia, osteopenia, faecal impaction, bed sores, and depression. 1 Few studies have been done on the effectiveness of hospital isolation techniques in preventing the spread of antibiotic resistant organisms, and none are convincing. Elderly people who survive hospital acquired infection with methicillin resistant S aureus are often discharged in a weakened, deteriorated state to a nursing home, where their condition improves. Fortunately, most nursing homes do not isolate these people, and yet spread to other residents, who by definition are chronically ill or disabled, seems to be low.
As pointed out by Crowcroft and Catchpole, 2 86% of those who died were elderly people. Isolation increases their invisibility. This is a double whammy for elderly people, who tolerate physical inactivity the least well and, at the same time, are the most likely to have their signs and symptoms not recognised by doctors. Perhaps in hospitals the wellbeing of older people takes a back seat to the threat of illness and death to younger people, hindering the investigation of the benefits and adverse effects from the intervention of isolation. 1 9 9 2 1 9 9 3 1 9 9 4 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 9 9 2 0 0 0 2 0 0 1 
Managing acute renal colic
Intramuscular diclofenac should be avoided
Editor-The article by Wright et al on managing the pain of ureteric colic in the community has raised some concerns. 1 The paper implies that a strategy of administering intramuscular diclofenac in the community would reduce the need for admitting patients to emergency departments. Although we welcome any attempt to reduce the number of unnecessary admissions to emergency departments, we raise the following points about using intramuscular diclofenac.
Firstly, diclofenac causes pain on injections with a concomitant rise in serum phosphokinase activity. Cases of necrotising fasciitis have been recorded. 2 Secondly, other non-steroidal antiinflammatory drugs may be used, such as sublingual piroxicam or intramuscular keterolac, that may prove as effective as diclofenac without damaging tissues. 3 4 Thirdly, cyclo-oxygenase 2 inhibitors may also prove effective in the treatment of renal colic and confer benefits in terms of their gastric protective effects. While clinical information is lacking in this area we believe that it is worthy of further analysis.
The defence unions have stated that intramuscular injections of diclofenac into the thigh are the least safe. The Committee on Safety for Medicines has received reports concerning this issue. None of the cases that were opened were defensible, and one of the recommendations suggested that alternative routes of administration be used where possible. 5 Such practice must therefore be able to withstand scrutiny in the event of a complaint or litigation.
Our trust has taken the step of withdrawing intramuscular diclofenac from the trust formulary. We prefer to use rectal diclofenac or one of the cyclo-oxygenase 2 inhibitors.
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